• May 7, 2021

A & L Canada Laboratories to be lead analytical testing facility in Shoppers Drug Mart and TruTrace Pilot Traceability Program for Medical Cannabis

A&L Canada Laboratories to participate as one of the primary testing facilities in the Pilot Program providing quality assurance in end use medicinal products

TORONTO and LONDON, ONTARIO — July 8, 2019 — A & L Canada Laboratories Inc. (“A&L”), a leader in analytical services and technologies, and TruTrace Technologies Inc. (CSE: TTT; OTC: TTTSF) (“TruTrace” or the “Company”), creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, announced today that A&L will be one of the inaugural testing facilities in the Shoppers Drug Mart (“Shoppers”) and TruTrace Technologies medical cannabis verification pilot program (the “Pilot Program”).

As announced by Shoppers at the second annual World Cannabis Congress, the Pilot Program is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products.

A&L was one of the earliest testing facilities to receive a Health Canada testing license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and provides a wide range of analytical services to the cannabis industry. A&L was recently presented the award for the Best Testing Facility at the 2019 O’Cannabiz Awards Gala – a national annual event honoring cannabis professionals and companies, recognizing excellence and innovation in the industry.

RELATED  Ten Tokyo Smoke Licensee Retail Cannabis Stores to Open in Ontario in Early 2020

“We provide the full range of services required by TruTrace and Shoppers, and we are proud to support the transparency and accountability goals of this Pilot Program. Our capabilities in testing through all stages of the cannabis production cycle will fully support the quality assurance mandate of Shoppers,” said Nevin McDougall, President and Chief Commercial Officer of A & L.

“We are very pleased to have secured the support of A&L to provide an essential element of the Pilot Program,” said TruTrace Technologies CEO Robert Galarza. “A fundamental objective of the program is to provide complete assurance to medical patients about the origins and quality of their cannabis. A&L’s testing services are a key aspect of meeting that objective.”

A & L will support the project by working with other pilot partners such as WeedMD Inc. and Zenabis Global to provide final test data on medical cannabis products, validating the functionality of the TruTrace platform and meeting the quality assurance requirements of Shoppers and the Canadian consumer.

RELATED  Organigram Receives Health Canada Approval to Bring Total Licensed Production Capacity to Target of 76,000 kg/yr1

The full diagnostic capabilities of A&L Canada Laboratories for the cannabis industry can be found on the company website at https://www.alcanada.com/cannabistesting

About TruTrace Technologies

TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.


Read Previous

GrowerIQ Announces Cutting-Edge Sensor Technology to Prevent Crop Loss

Read Next

Premiers Focused on Public Health and Safety in the Legalization of Cannabis